利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

8 条记录 (耗时 0.015 秒)

    Corneal opacification inhibitory composition
    1.
    发明授权
    Corneal opacification inhibitory composition 失效
    角膜不透明抑制组成

    公开(公告)号：US5710148A

    公开(公告)日：1998-01-20

    申请号：US611465

    申请日：1996-03-04

    申请人： Katsuichi Sudo ,  Yasuko Umegaki ,  Yasushi Okumura

    发明人： Katsuichi Sudo ,  Yasuko Umegaki ,  Yasushi Okumura

    IPC分类号： A61K31/336 ,  A61K31/395 ,  A61K31/335 ,  A61K31/38

    CPC分类号： A61K31/336 ,  Y10S514/912

    摘要： An ophthalmic preparation which comprises a fumagillol derivative represented by the general formula(I): ##STR1## wherein R.sup.1 is hydrogen; R.sup.2 is a halogen, N(O).sub.m R.sup.5 R.sup.6, N.sup.+ R.sup.5 R.sup.6 R.sup.7 .multidot.X.sup.-, S(O).sub.n R.sup.5 or S.sup.+ R.sup.5 R.sup.6 .multidot.X.sup.-, wherein R.sup.5, R.sup.6 and R.sup.7 represent independently a substituted or unsubstituted hydrocarbon group or a substituted or unsubstituted heterocyclic group; X.sup.- represents a counter anion; m represents 0 or 1; n represents an integer from 0 to 2; or R.sup.5 and R.sup.6 together with the adjacent nitrogen or sulfur atom may form a substituted or unsubstituted nitrogen- or sulfur-containing heterocyclic group which may form a condensed ring; or R.sup.1 and R.sup.2 are combined to represent a chemical bond; R.sup.3 is a substituted or unsubstituted 2-methyl-l-propenyl group or a substituted or unsubstituted isobutyl group; A is oxygen or NR.sup.8, wherein R.sup.8 represents hydrogen, a substituted or unsubstituted lower alkyl group or a substituted or unsubstituted aryl group; and R.sup.4 is hydrogen, a substituted or unsubstituted hydrocarbon group or a substituted or unsubstituted acyl group and a salt thereof is useful for inhibiting corneal opacification occurring after ophthalmic surgery.

    摘要翻译： 一种眼用制剂，其包含由通式（I）表示的烟曲霉醇衍生物：其中R 1是氢; R2是卤素，N（O）mR5R6，N + R5R6R7XX-，S（O）nR5或S + R5R6XX-，其中R5，R6和R7独立地表示取代或未取代的烃基或取代或未取代的杂环基; X-表示抗衡阴离子; m表示0或1; n表示0〜2的整数， 或者R 5和R 6与相邻的氮原子或硫原子一起形成可以形成稠环的取代或未取代的含氮或硫的杂环基; 或R1和R2组合以表示化学键; R3是取代或未取代的2-甲基-1-丙烯基或取代或未取代的异丁基; A是氧或NR8，其中R8表示氢，取代或未取代的低级烷基或取代或未取代的芳基; R 4为氢，取代或未取代的烃基或取代或未取代的酰基及其盐可用于抑制眼外科手术后发生的角膜混浊。

    Angiostatic agents
    2.
    发明授权
    Angiostatic agents 失效
    血管抑制剂

    公开(公告)号：US5135920A

    公开(公告)日：1992-08-04

    申请号：US434440

    申请日：1989-11-09

    申请人： Tsuneo Kanamaru ,  Yukimasa Nozaki ,  Katsuichi Sudo

    发明人： Tsuneo Kanamaru ,  Yukimasa Nozaki ,  Katsuichi Sudo

    IPC分类号： A61K9/06 ,  A61K31/715

    CPC分类号： A61K9/06 ,  A61K31/715 ,  Y10S514/824 ,  Y10S514/863 ,  Y10S514/866

    摘要： Dextran sulfate, .beta.-1,3-glucan sulfate, and the salts thereof are angiostatic and useful for treatment and prevention of various diseases caused by abnormally accelerated angiogenesis. Combination of such a compound with a steroidal or non-steroidal substance increases the angiostatic activity of each compound to induce the combined effect.

    摘要翻译： 硫酸葡聚糖，β-1,3-葡聚糖硫酸盐及其盐是血管抑制性的，可用于治疗和预防由异常加速的血管发生引起的各种疾病。 这种化合物与甾体或非甾体物质的组合增​​加每种化合物的血管生成活性以诱导组合效应。

    AGENT FOR PREVENTING AND/OR TREATING FUNCTIONAL GASTROINTESTINAL DISORDER
    3.
    发明申请
    AGENT FOR PREVENTING AND/OR TREATING FUNCTIONAL GASTROINTESTINAL DISORDER 有权
    用于预防和/或治疗功能性胃肠疾病的药剂

    公开(公告)号：US20110152517A1

    公开(公告)日：2011-06-23

    申请号：US13061239

    申请日：2009-09-24

    申请人： Satoru Tamaoki ,  Jun Sato ,  Katsuichi Sudo

    发明人： Satoru Tamaoki ,  Jun Sato ,  Katsuichi Sudo

    IPC分类号： C07D491/22

    CPC分类号： A61K31/439 ,  A61K9/1652 ,  A61K9/2018 ,  A61K9/2054

    摘要： A preventive and/or therapeutic agent which improves an abnormal bowel function such as an abdominal pain, a diarrhea, or a constipation and is effective for preventing or treating a functional gastrointestinal disorder is provided.A preventive and/or therapeutic agent for a functional gastrointestinal disorder contains refaximin as an effective ingredient. The functional gastrointestinal disorder includes a functional esophageal disorder, a functional gastroduodenal disorder (e.g., a functional dyspepsia), a functional bowel disorder (e.g., a functional bloating, a functional diarrhea), a functional abdominal pain syndrome, a functional gallbladder and Sphincter of Oddi disorder, a functional anorectal disorder (e.g., a functional fecal incontinence, a functional anorectal pain, a functional defecation disorder), a functional disorder in neonates and toddlers (e.g., an infant functional diarrhea), a functional disorder in children and adolescents (e.g., a childhood functional abdominal pain, a childhood nonretentive fecal incontinence), and other diseases.

    摘要翻译： 提供了改善肠功能异常的预防和/或治疗剂，例如腹痛，腹泻或便秘，并且对于预防或治疗功能性胃肠道疾病是有效的。 用于功能性胃肠道疾病的预防和/或治疗剂含有抗纤维蛋白作为有效成分。 功能性胃肠道疾病包括功能性食管障碍，功能性胃十二指肠疾病（例如功能性消化不良），功能性肠病（例如功能性腹胀，功能性腹泻），功能性腹痛综合征，功能性胆囊和括约肌 Oddi障碍，功能性肛门直肠疾病（例如，功能性大便失禁，功能性肛门直肠疼痛，功能性排便障碍），新生儿和幼儿中的功能障碍（例如，婴儿功能性腹泻），儿童和青少年功能障碍（ 例如儿童功能性腹痛，童年无力大便失禁）和其他疾病。

    Cyclodextrin complex of fumagillin derivative
    4.
    发明授权
    Cyclodextrin complex of fumagillin derivative 失效
    FUMAGILLIN衍生物的CYCLODEXTRIN复合物

    公开(公告)号：US5196406A

    公开(公告)日：1993-03-23

    申请号：US704347

    申请日：1991-05-23

    申请人： Shigeru Kamei ,  Hiroaki Okada ,  Katsuichi Sudo ,  Shoji Kishimoto

    发明人： Shigeru Kamei ,  Hiroaki Okada ,  Katsuichi Sudo ,  Shoji Kishimoto

    IPC分类号： A61K31/335 ,  A61K47/48

    CPC分类号： B82Y5/00 ,  A61K31/335 ,  A61K47/48969

    摘要： A complex of a fumagillin derivative represented by the general formula: ##STR1## wherein R.sup.1 is hydrogen; R.sup.2 is halogen, N(O)mR.sup.5 R.sup.6, N.sup.+ R.sup.5 R.sup.6 R.sup.7.X.sup.-, S(O)nR.sup.5 or S.sup.+ R.sup.5 R.sup.6.X.sup.- (wherein R.sup.5, R.sup.6 and R.sup.7 are independently an optionally substituted hydrocarbon or heterocyclic group; X.sup.- is a counter anion; m is an integer of 0 or 1; n is an integer from 0 to 2; and R.sup.5 and R.sup.6 together with the adjacent nitrogen or sulfur atom may form a nitrogen- or sulfur-containing heterocyclic group which may be substituted and form a condensed ring); or R.sup.1 and R.sup.2 together represent a bond; R.sup.3 is 2-methyl-1-propenyl group or isobutyl group; A is O or NR.sup.8 (wherein R.sup.8 is hydrogen or an optionally substituted lower alkyl or aryl group); R.sup.4 is hydrogen, an optionally substituted hydrocarbon group or an optionally substituted acyl group); or a salt thereof, with an optionally etherified cyclodextrin is disclosed. The present invention also provides an antineoplastic agent containing the complex.

    Agent for preventing and/or treating functional gastrointestinal disorder
    5.
    发明授权
    Agent for preventing and/or treating functional gastrointestinal disorder 有权
    用于预防和/或治疗功能性胃肠道疾病的药剂

    公开(公告)号：US08980872B2

    公开(公告)日：2015-03-17

    申请号：US13061239

    申请日：2009-09-24

    申请人： Satoru Tamaoki ,  Jun Sato ,  Katsuichi Sudo

    发明人： Satoru Tamaoki ,  Jun Sato ,  Katsuichi Sudo

    IPC分类号： A61K31/33 ,  C07D498/00 ,  A61K31/439 ,  A61K9/16 ,  A61K9/20

    CPC分类号： A61K31/439 ,  A61K9/1652 ,  A61K9/2018 ,  A61K9/2054

    摘要： A method for preventing and/or treating a functional gastrointestinal disorder, comprising administering, to a subject with the functional gastrointestinal disorder, rifaximin as an effective ingredient. The functional gastroinstestinal disorder includes a functional esophageal disorder, a functional gastroduodenal disorder (e.g., a functional dyspepsia), a functional bowel disorder (e.g., a functional bloating, a functional diarrhea), a functional abdominal pain syndrome, a functional gallbladder and Sphincter of Oddi disorder, a functional anorectal disorder (e.g., a functional fecal incontinence, a functional anorectal pain, a functional defecation disorder), a functional disorder in neonates and toddlers (e.g., an infant functional diarrhea), a functional disorder in children and adolescents (e.g., a childhood functional abdominal pain, a childhood nonretentive fecal incontinence), and other diseases.

    摘要翻译： 一种预防和/或治疗功能性胃肠道疾病的方法，包括给具有功能性胃肠道疾病的受试者施用利福昔明作为有效成分。 功能性胃肠道疾病包括功能性食管障碍，功能性胃十二指肠疾病（例如功能性消化不良），功能性肠病（例如功能性腹胀，功能性腹泻），功能性腹痛综合征，功能性胆囊和括约肌 Oddi障碍，功能性肛门直肠疾病（例如，功能性大便失禁，功能性肛门直肠疼痛，功能性排便障碍），新生儿和幼儿中的功能障碍（例如，婴儿功能性腹泻），儿童和青少年功能障碍（ 例如儿童功能性腹痛，童年无力大便失禁）和其他疾病。

    Combined pharmaceutical composition
    6.
    发明申请
    Combined pharmaceutical composition 审中-公开
    组合药物组合物

    公开(公告)号：US20070197602A1

    公开(公告)日：2007-08-23

    申请号：US10588725

    申请日：2005-02-08

    申请人： Hashime Kanazawa ,  Kouki Ishitani ,  Katsuichi Sudo ,  Naoto Tanimori

    发明人： Hashime Kanazawa ,  Kouki Ishitani ,  Katsuichi Sudo ,  Naoto Tanimori

    IPC分类号： A61K31/44 ,  A61K31/19 ,  A61K31/21 ,  A61K31/35

    CPC分类号： A61K45/06 ,  A61K31/192 ,  A61K31/194 ,  A61K31/216 ,  A61K31/22 ,  A61K31/366 ,  A61K31/40 ,  A61K31/405 ,  A61K31/4418 ,  A61K31/445 ,  A61K31/47 ,  A61K31/7008 ,  A61K31/7028 ,  A61K2300/00

    摘要： At least one hyperlipidemic agent selected from the group consisting of a fibrate compound (e.g., fenofibrate, bezafibrate, or a salt thereof) and an HMG-CoA reductase inhibitor (e.g., a statin compound, for example, pravastatin, atorvastatin, or salts thereof) is, as active ingredients, combined with an α-glucosidase inhibitor (e.g., voglibose, and acarbose) in the pharmaceutical composition of the present invention. The proportion of the α-glucosidase inhibitor may be about 0.001 to 50 parts by weight relative to 100 parts by weight of the hyperlipidemic agent. The present invention provides a pharmaceutical composition which is excellent in prophylactic and/or therapeutic effect on metabolic syndrome, hyperlipemia, diabetes, diabetes complications, etc, and has few side effects.

    摘要翻译： 至少一种选自贝特类化合物（例如非诺贝特，苯扎贝特或其盐）和HMG-CoA还原酶抑制剂（例如他汀类化合物，例如普伐他汀，阿托伐他汀或其盐的高脂血症药物 ）作为活性成分与本发明的药物组合物中的α-葡糖苷酶抑制剂（例如伏格列酮和阿卡波糖）组合。 相对于100重量份的高脂血症药，α-葡糖苷酶抑制剂的比例可以为约0.001至50重量份。 本发明提供了对代谢综合征，高脂血症，糖尿病，糖尿病并发症等的预防和/或治疗效果优异的副作用少的药物组合物。